Clinical Trial

Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Objective to compare the efficacy and safety of TQB2450 injection combined with anlotinib and chemotherapy, and TQB2450 injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer subjects who failed to receive first-line chemotherapy combined with immunization, and to explore and evaluate biomarkers related to efficacy, mechanism of action / resistance mechanism, and safety.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-15.
Trial Details
NCT Number NCT06141226
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Non-small-cell Lung Cancer
Enrollment 148 participants
Start Date 2023-04-12
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-19